PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome [Yah...
X4 Pharmaceuticals, Inc. (XFOR)
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
States, today announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDI™ (mavorixafor), recently approved by the U.S. Food and Drug Administration (FDA) and the first FDA-approved therapy specifically indicated for use in patients 12 years of age and older with warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome. WHIM syndrome is a rare, combined primary immunodeficiency and chronic neutropenic disorder caused by reduced mobilization of white blood cells into the peripheral circulation due to CXCR4/CXCL12 pathway dysfunction. It is estimated that at least 1,000 people are currently diagnosed with WHIM syndrome in the U.S. XOLREMDI, a once-daily oral treatment option, is a selective antagonist of the CXCR4 receptor that blocks the binding of the CXCL12 ligand to the CXCR4 receptor. By targeting the underlying cause of WHIM syndrome, treatment with XOLREMDI results in the increased mobilization of immune cells from the bone marrow.
Show less
Read more
Impact Snapshot
Event Time:
XFOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XFOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XFOR alerts
High impacting X4 Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
XFOR
News
- X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference [Yahoo! Finance]Yahoo! Finance
- X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewswire
- X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility [Yahoo! Finance]Yahoo! Finance
- X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan FacilityGlobeNewswire
- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
XFOR
Earnings
- 5/7/24 - Miss
XFOR
Analyst Actions
- 3/22/24 - HC Wainwright
XFOR
Sec Filings
- 5/9/24 - Form 8-K
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- XFOR's page on the SEC website